Danielle Smith took the opportunity to highlight the UK’s alignment with her recent trans policy announcements that had sent far-left media and politicians into a frenzy over the impact they’d have on so-called “trans kids.”
A policy update released on Tuesday by the UK’s National Health Service (NHS) found there is not enough evidence to support the safety or effectiveness of puberty blockers, and banned the prescription of them to youth aged 16 and under.
Smith, who just two months prior announced that she was banning the prescription of puberty blockers and hormone therapy to minors, told a reporter during a recent press conference that there is “increasing international evidence” to support her policies.
Smith referenced the NHS stating she’s focusing on the “broader international picture.”
“We want to make sure kids are making these decisions when they are old enough to understand the consequences,” Smith said.
“We are talking about sterility — let’s be frank about it.”
Smith further noted that along with the UK, many Nordic countries are taking a different approach than what doctors in Canada seem to be taking, where many advocate for the use of puberty blockers on minors.
“We have agreed that we believe that children who have good medical care, psychological support and supportive family can start that when they’re sixteen. I think that increasingly is going to be supported by the international evidence,” Smith concluded.
Smith had dealt with harsh accusations for her recent policy announcements from far-left media and politicians, often calling her “anti-LGBT.” One NDP MLA, Janis Irwin, literally cried in public while speaking about the horrors of banning biological men from women’s sports, and protecting confused youth from making irreversible health decisions.
Details of England’s decision
On Tuesday, the NHS announced that more trials need to take place before prescribing puberty blockers as a safe treatment for minors who think they are transgender.
Their website now states “puberty blockers (gonadotrophin-releasing hormone analogues) are not available to children and young people for gender incongruence or gender dysphoria because there is not enough evidence of safety and clinical effectiveness.”
It further mentioned that “these hormones cause some irreversible changes, such as:
- breast development (caused by taking oestrogen)
- breaking or deepening of the voice (caused by taking testosterone)”
“Long-term cross-sex hormone treatment may cause temporary or even permanent infertility,” it adds.
